scholarly journals OFT condemns the Pharmaceutical Price Regulation Scheme

Prescriber ◽  
2007 ◽  
Vol 18 (15) ◽  
pp. 20-22
Author(s):  
Steve Chaplin
Keyword(s):  
Price Regulation ◽  
Pharmaceutical Price ◽  
Pharmaceutical Price Regulation Scheme ◽  
Regulation Scheme

Announcement

1993 ◽  
Vol 31 (14) ◽  
pp. 56-56
Keyword(s):  
Pharmaceutical Industry ◽  
Health Economics ◽  
Price Regulation ◽  
Senior Managers ◽  
Pharmaceutical Price ◽  
Pharmaceutical Price Regulation Scheme ◽  
Therapeutics Bulletin ◽  
Regulation Scheme ◽  
Department Of Health

On Wednesday 15 SeptemberDrug & Therapeutics Bulletin will be holding a seminar on the “Implications of the new Pharmaceutical Price Regulation Scheme”. The seminar, which will take place at 2, Marylebone Road, London from 2.00 – 5.00pm, will be addressed by Melvyn Jeremiah, Under Secretary, Department of Health, Andrew Towse, Director, Office of Health Economics, Jane Richards, who chairs the Prescribing Sub-Committee, GMSC and Nick Bosanquet, Professor of Economics. The afternoon should interest health economists, senior managers in the pharmaceutical industry, government officers, NHS administrators and doctors concerned with costs issues. Those wishing to attend should send a cheque for £58.75 (includes VAT) payable to Consumers’ Association to: DTB seminar, 2 Marylebone Road, London NW1 4DF. Because of the very limited seating (50 places at most), applications plus payment should not be delayed. We have not applied for PGEA approval.

DTB position on drug costs

1993 ◽  
Vol 31 (11) ◽  
pp. 44-44
Keyword(s):  
Price Regulation ◽  
Comparative Data ◽  
Drug Costs ◽  
Pharmaceutical Price ◽  
Pharmaceutical Price Regulation Scheme ◽  
Individual Drug ◽  
Regulation Scheme ◽  
Department Of Health ◽  
Drug Companies ◽  
Branded Drugs

When producing articles for the Drug and Therapeutics Bulletin we seek comparative data on the drugs under discussion, and recommend the use of a product only if we think that on balance it offers advantages in terms of effectiveness, safety, convenience and (lastly) cost over other drugs or treatments already available. The Drug Costs symposium made it clear that the price of the drug alone indicates actual expenditure by the NHS only crudely, and that other variables (length of illness or stay in hospital, altered needs for surgery or investigations) need to be taken into account if real comparisons are to be made. The symposium also reminded prescribers that the price of branded drugs paid by the NHS depends on confidential negotiations between the Department of Health and individual drug companies through the Pharmaceutical Price Regulation Scheme (PPRS). Because negotiations are done in private it remains unclear how savings by prescribers are translated into savings to the NHS. Moreover the terms of the scheme encourage the proliferation of (‘me-too’) drugs, the setting of high prices at a drug’s launch, and the use of promotion that is aggressive.

Correction: happy families in the pharmaceutical industry (October 7, p78)

1983 ◽  
Vol 21 (25) ◽  
pp. 100-100
Keyword(s):  
Pharmaceutical Industry ◽  
Sales Force ◽  
Price Regulation ◽  
Transitional Period ◽  
Pharmaceutical Companies ◽  
Pharmaceutical Price ◽  
Pharmaceutical Price Regulation Scheme ◽  
Regulation Scheme

Although pharmaceutical companies may obtain tax advantages by creating one or more subsidiaries, we were wrong to suggest that they can obtain increased promotional allowance under the Pharmaceutical Price Regulation Scheme (PPRS). However, small subsidiaries with separate sales force and management that are survivors of a take-over may be given a separate allowance for a transitional period until they have had time to merge. We understand from people in the industry that the overriding reason for setting up subsidiaries is to increase their impact on doctors through their reps.

New terms for the pharmaceutical price regulation scheme

1993 ◽  
Vol 31 (26) ◽  
pp. 103-104
Keyword(s):  
Price Regulation ◽  
Pharmaceutical Price ◽  
Pharmaceutical Price Regulation Scheme ◽  
Individual Drug ◽  
Regulation Scheme ◽  
Department Of Health ◽  
Drug Companies ◽  
The Uk

The overall cost for drugs prescribed in the UK is fixed in negotiations between the Department of Health (DoH) and individual drug companies. New terms for the Pharmaceutical Price Regulation Scheme (PPRS), which govern these negotiations, came into effect in October and will operate till April 1998.1 In this article we discuss the PPRS itself and consider whether the new terms offer any advance over previous arrangements which we have criticised.2,3

OP20 When Are Nationally Available Discounts Introduced In NICE Appraisals

2018 ◽  
Vol 34 (S1) ◽  
pp. 9-9
Author(s):  
Kathleen Noon ◽  
Christopher Painter ◽  
Stephen Montgomery
Keyword(s):  
Temporal Pattern ◽  
Price Regulation ◽  
Pharmaceutical Price ◽  
Pharmaceutical Price Regulation Scheme ◽  
Appraisal Process ◽  
Regulation Scheme ◽  
Price Flexibility ◽  
Positive Recommendation

Introduction:Offering a nationally available discount has become common to increase the chance of being recommended by the National Institute of Health and Care Excellence (NICE). This study reviewed all NICE technology appraisals (TAs) since October 2007 to determine whether a national available discount was submitted, and explore when these discounts were introduced.Methods:All TAs between October 2007 and August 2017 were reviewed. The timing of the nationally available discount submission was allocated into one of four categories: initially submitted; initially submitted but changed; introduced after submission; or, other discount. An analysis was conducted to examine whether there was a temporal pattern in the introduction of nationally available discounts before or after January 2014, when the current Pharmaceutical Price Regulation Scheme (PPRS) came into effect.Results:Before 1 January 2014, a nationally available discount was only used in the minority of cases across recommended (22 percent of cases) and not recommended (19 percent) technologies. In the period since 1 January 2014, use of a nationally available discount increased overall, but to a greater degree in technologies ultimately receiving a positive recommendation from NICE (not recommended: 19 percent to 39 percent; recommended: 22 percent to 59 percent). In the period since 1 January 2014, the proportion of technologies with a positive recommendation where implicit price flexibility during the appraisal was revealed increased (from 20/186) to 40/182.Conclusions:With the current PPRS, the majority of technologies have offered a nationally available discount, most commonly at the time of submission; however, there is increasing evidence of implicit price flexibility during the appraisal process to achieve a positive recommendation.

Sign in / Sign up

Export Citation Format

Share Document